In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...

Novartis AG announced disappointing sales for a key psoriasis drug and the looming retirement of its respected finance chief, ...

Novartis ( NYSE: NVS) CEO Vas Narasimhan said the company has built up its U.S. inventories to help mitigate the impact of ...

President Donald Trump's proposed tariffs on pharmaceuticals could lead to higher prices, higher insurance premiums, and even drug shortages, experts say.

Johnson & Johnson (J&J) has halved its expectations for costs this year related to new tariffs and raised its full-year sales ...

Novartis (NVS) raised its full-year profit outlook thanks to strong demand for some of its key drugs. Novartis CEO Vas ...

American consumers of Korean cosmetics and skin-care products are bulk buying, as President Trump threatens 25 percent ...

By Miranda Murray and Patricia Weiss BERLIN (Reuters) -Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong second-quarter sales of key drugs such as Kisqali, ...

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...

Rather than continuing to retaliate with tariffs of its own, the Canadian government has begun to confess that such a tactic ...

On Thursday, oil prices climbed, defying the backdrop of softening global trade tensions. Experts attribute this rise to ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...